“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” —Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut

Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease.

Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease-Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation.

This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject.

Contents

Contributors

Preface

Acknowledgments

1. History of Cancer Immunotherapy

William Kelly, Michael T. Lotze, and Michael B. Atkins

SECTION I: BASIC PRINCIPLES OF TUMOR IMMUNOLOGY

Francesco M. Marincola

2. Introduction to Basic Sciences—Cracking the Code of Cancer Immune Responsiveness and the Evolution of Cancer Biology

Francesco M. Marincola and Michael T. Lotze

3. Human Tumor Antigens Recognized by T Lymphocytes

Orian Bricard, Nicolas van Baren, and Pierre G. Coulie

4. HLA Class I Antigen-Processing Machinery in Cancer

Lei Cai, Theodoros Michelakos, Teppei Yamada, Song Fan, Joseph H. Schwab, Cristina R. Ferrone, and Soldano Ferrone

5. Systems Biology of T Cells

David Furman

6. Activation of CD4+ T Lymphocytes

Abul K. Abbas and Lucy S. K. Walker

7. Regulation of Cell-Mediated Immunity: The Biology of Checkpoints and Regulatory T Cells

Lucy S. K. Walker and Abul K. Abbas

8. The Role of Breg Cells in Modulating the Antitumor Immune Response

Yu Zhang, Bonnie Blomberg, and Joseph D. Rosenblatt

9. The Innate Immune System: Natural Killer Cells

Julie Y. Djeu and Melba Marie Tejera

10. The Innate Immune System: Macrophages

Alberto Mantovani and Isabella Barajon

11. Natural Killer Cell Effector Mechanisms Against Solid Tumors and Leukemias and Their Exploitation in Immunotherapy

Andrea De Maria, Lorenzo Moretta, Gabriella Pietra, and Massimo Vitale

12. Role of the Microbiota in Homeostasis, Carcinogenesis, and Therapy

Ernesto Perez-Chanona and Giorgio Trinchieri

13. Chemokines and Chemokine Receptors: Regulators of the Balance Between Antitumor and Protumor Immunity and Promising Targets in Cancer Immunotherapy

Genyuan Zhu, Michelle M. Appenheimer, James J. Mulé, and Sharon S. Evans

14. Role of the Tumor Microenvironment

David H. Munn and Vincenzo Bronte


SECTION II: CANCER IMMUNOTHERAPY TARGETS AND CLASSES

Thomas F. Gajewski

15. Introduction to Principles of Cancer Immunotherapy

Thomas F. Gajewski

16. Manipulating Innate Immune Pathways as Cancer Immunotherapy

Thomas F. Gajewski

17. Cancer Vaccines: Considerations of Antigen, Formulation, and Delivery

Rachel Perret, Alena Donda, and Pedro Romero

18. T Cell Modulatory Cytokines

Emanuela Romano and Kim Margolin

19. Adoptive T Cell Transfer

Shivani Srivastava, Alexander I. Salter, and Stanley R. Riddell

20. Immunotherapy Based on Blocking T Cell Inhibitory Pathways

Randy F. Sweis and Jason J. Luke

21. Agonistic Antibodies to Co-Stimulatory Molecules

Rebekka Duhen and Andrew D. Weinberg

22. Immune Effects of Conventional Cancer Therapeutics

Sandra Demaria and Lorenzo Galluzzi

23. Oncolytic Viruses

Larissa Pikor, John C. Bell, and Howard L. Kaufman

24. Principles of Combination Immunotherapies

Morganna Freeman, Raphael Moreira, Omid Hamid, and Patrick A. Ott

SECTION III: IMMUNE FUNCTION IN CANCER PATIENTS

Lisa H. Butterfield

25. Introduction to Immune Function in Cancer Patients

Lisa H. Butterfield

26. Tumor-Infiltrating Immune Cells of Myeloid Origin

Dmitriy W. Gutkin and Michael R. Shurin

27. Intratumoral Gene Signatures and Host Genetic Variations Associated With Immune Responsiveness

Davide Bedognetti, Zohreh Tatari-Calderone, Francesco M. Marincola, and Ena Wang

28. Impact of Somatic Mutations on the Local and Systemic Antitumor Immune Response

Paul F. Robbins and Stefani Spranger

29. Tumor Antigen Profiling

Robert Saddawi-Konefka and Jack D. Bui

30. Assessment of Antitumor Immunity in Blood and Lymph Nodes

Priyanka B. Subrahmanyam, Lisa H. Butterfield, Peter P. Lee, and Holden T. Maecker

31. Regulatory T Cell Biology and Its Application in Cancer

Ilona Kryczek, Timothy Frankel, and Weiping Zou

32. Systemic Measures of Immune Function in Cancer Patients: Other Suppressive Cellular Mechanisms

Raju R. Raval and William E. Carson III

33. Circulating Mediators of Tumor-Induced Immune Suppression

Theresa L. Whiteside

34. The Multifaceted Roles of B Cells and Plasma Cells in Antitumor Immunity

Maartje C. A. Wouters and Brad H. Nelson

35. Systems Immunology Approaches to Cancer Immunotherapy

Damien Chaussabel

36. Tumor Microenvironment Metabolism as a Primordial Checkpoint in Antitumor T Cell Immunity

Greg M. Delgoffe

37. Age-Related Immune Function Changes as They Relate to Cancer Immunotherapy

Graham Pawelec

38. Clinical Measures: Imaging, Pseudoprogression, and Metabolism

Max M. Wattenberg and Lawrence Fong


SECTION IV: DISEASE-SPECIFIC TREATMENTS AND OUTCOMES

Paolo A. Ascierto

39. Introduction: General Approach to Cancer Immunotherapy—Lessons Learned From the Past Years

Paolo A. Ascierto

40. Immunotherapy in Melanoma

Antonio M. Grimaldi, Michael Postow, and Paolo A. Ascierto

41. Other Cutaneous Tumors: Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, and Merkel Cell Carcinoma

Jürgen C. Becker and Selma Ugurel

42. Immunotherapy in Genitourinary Malignancies

Moshe C. Ornstein and Brian I. Rini

43. Immunotherapy in Gastrointestinal Cancers

Mihir M. Shah and Usha Malhotra

44. Immunotherapy of Hepatocellular Carcinoma

Delia D’Avola, Ignacio Melero, and Bruno Sangro

45. Immunotherapy for Gynecologic Malignancies

Kunle Odunsi, Maria Agarwal, Thinle Chodon, and Cornelia L. Trimble

46. Breast Cancer Immunotherapy

Leisha A. Emens and Rita Nanda

47. Lung Cancer

Maria A. Velez, Yi-Long Wu, Steven M. Dubinett, Zhong-Yi Dong, Si-Pei Wu, and Edward B. Garon

48. Head and Neck Cancer

Nicole C. Schmitt and Robert L. Ferris

49. Immunotherapy of Hematologic Malignancies: Lymphomas, Leukemias, and Myeloma

John M. Timmerman and Patricia A. Young

50. Brain Tumors

Hideho Okada and Noriyuki Kasahara

51. Sarcomas

Paolo G. Casali, Silvia Stacchiotti, Dario Sangiolo, Chiara Castelli, and Angelo Paolo Dei Tos

52. Pediatric Cancers: Neuroblastoma

Maya Suzuki and Nai-Kong V. Cheung


SECTION V: REGULATORY ASPECTS OF CANCER IMMUNOTHERAPY

Raj K. Puri

53. A Regulatory Perspective on Cell Therapy for Cancer: Chemistry, Manufacturing and Control, and Preclinical and Clinical Considerations

Ke Liu, Robert Q. Le, Robert Sokolic, Thomas Finn, Brian Niland, Allen Wensky, and Raj K. Puri

54. Gene Therapy-Based Immunotherapy Products for Human Clinical Trials: Chemistry, Manufacturing and Control, Preclinical and Clinical Considerations—An FDA Perspective

Robert Sokolic, Xiaobin Lu, Ramjay Vatsan, Allen Wensky, Robert Q. Le, Ke Liu, and Raj K. Puri

55. Regulatory Considerations for In Vitro Diagnostic Devices

Pamela Bradley

Index